Funding Opportunities

NIH Funding Opportunities

Notice of Change to Funding Opportunity Announcement PA-17-098 "Administrative Supplements for Research on Sexual and Gender Minority (SGM) Populations (Admin Supp)"
Notice NOT-OD-17-036 from the NIH Guide for Grants and Contracts
Thu, 19 Jan 2017 08:41:48 EST

NIH Implementation of the Interim-RPPR while a Renewal Application is Under Consideration
Notice NOT-OD-17-037 from the NIH Guide for Grants and Contracts
Thu, 19 Jan 2017 01:29:32 EST

Notice of the Publication of the Final Rule on the Federal Policy for the Protections of Human Subjects (Common Rule)
Notice NOT-OD-17-038 from the NIH Guide for Grants and Contracts
Thu, 19 Jan 2017 01:40:09 EST

Registration Open for the Spring 2017 NIH Regional Seminar on Program Funding and Grants Administration - New Orleans, Louisiana
Notice NOT-OD-17-039 from the NIH Guide for Grants and Contracts
Thu, 19 Jan 2017 01:55:39 EST

Clarification of Number of Health Care System Partners Required for RFA-RM-16-019 NIH Health Care Systems Research Collaboratory - Demonstration Projects for Pragmatic Clinical Trials (UG3/UH3)
Notice NOT-RM-17-007 from the NIH Guide for Grants and Contracts
Tue, 17 Jan 2017 01:17:25 EST

Sex Hormone Induced Thromboembolism in Pre-Menopausal Women (R61/R33)
Funding Opportunity RFA-HL-18-003 from the NIH Guide for Grants and Contracts. The primary objective of the work to be supported by this funding opportunity is to understand the mechanisms by which female sex hormones and sex hormone-based therapies can increase the risk of venous and arterial thromboembolism in pre-menopausal women. Understanding the basic physiopathology of how sex hormones may induce or add to the pre-existing risk of thrombosis will strengthen our understanding of the mechanisms underlying thrombus formation in relevant clinical situations such as peripartum or in women using contraceptives or undergoing in vitro fertilization. Such research may help identify women at higher thrombotic risk and thus help guide their clinical care. It could also lead to the identification of potential new therapeutics to prevent thrombus formation. The FOA purpose does not include research on thromboembolism related comorbidities in post-menopausal women.
Tue, 17 Jan 2017 02:33:38 EST

Research Program Award (R35)
Funding Opportunity RFA-NS-17-020 from the NIH Guide for Grants and Contracts. The purpose of the NINDS Research Program Award (RPA) is to provide longer-term support and increased flexibility to Program Directors (PDs) /Principal Investigators (PIs) whose outstanding records of research achievement demonstrate their ability to make major contributions to neuroscience. RPAs will support the overall research programs of NINDS-funded investigators for up to 8 years, at a level commensurate with a PD/PIs recent NINDS support (Part 2, Section II) This greater funding stability will provide investigators with increased freedom and flexibility which may allow them to be more adventurous in their research, to take greater risks, to embark upon research that breaks new ground, to undertake research projects that require a longer timeframe, and/or to extend previous discoveries in new directions. Research supported through the RPA must be within the scope of the NINDS mission (http://www.ninds.nih.gov/about_ninds/mission.htm). Research activities outside of the NINDS mission, or traditionally supported by another NIH Institute or Center will not be considered through this program.
Thu, 19 Jan 2017 09:52:49 EST

Zika Virus (ZIKV) Complications (R21)
Funding Opportunity PA-17-085 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to provide support for research on Zika virus (ZIKV) and its complications. This FOA replaces PAR-16-106 which had used rolling application due dates to facilitate the rapid review and award of particularly urgent or time-sensitive projects. The last date for submitting an application to PAR-16-106 is January 13, 2017.
Tue, 17 Jan 2017 02:20:39 EST

Biomarkers for Diabetes, Digestive, Kidney and Urologic Diseases Using Biosamples from the NIDDK Repository (R01)
Funding Opportunity PAR-17-123 from the NIH Guide for Grants and Contracts. This FOA will provide support for assays (and associated data analysis) of repository-held samples for studies focused on an NIDDK relevant disease. The review of applications to this FOA will consider both access to repository-held samples and funding for assays using the samples. These studies are expected to generate scientific discoveries on disease mechanisms, disease pathogenic processes, disease progression, or clinical responses. Projects that make good use of the associated data from the clinical trials and studies, the original intent of the clinical study and/or trial are highly encouraged. Exploratory studies and discovery research are encouraged especially when samples are not severely limited, the work is justified, and the goal is consistent with the original intent of the clinical research.
Tue, 17 Jan 2017 01:37:28 EST

Perception and Cognition Research to Inform Cancer Image Interpretation (R21)
Funding Opportunity PAR-17-124 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to facilitate research on the perceptual and cognitive processes underlying the performance of cancer image observers in radiology and pathology, in order to improve the accuracy of cancer detection and diagnosis. This FOA utilizes the Exploratory/Developmental Grant (R21) mechanism, which supports investigation of novel scientific ideas or new model systems, tools, or technologies that have the potential for significant impact on biomedical or biobehavioral research. An R21 grant application need not have extensive background material or preliminary information.
Wed, 18 Jan 2017 09:27:49 EST

Perception and Cognition Research to Inform Cancer Image Interpretation (R01)
Funding Opportunity PAR-17-125 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to facilitate research on the perceptual and cognitive processes underlying the performance of cancer image observers in radiology and pathology, in order to improve the accuracy of cancer detection and diagnosis.
Wed, 18 Jan 2017 09:27:43 EST

Juvenile Protective Factors and Their Effects on Aging (R01)
Funding Opportunity PAR-17-126 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to invite: 1) descriptive studies to identify putative juvenile protective factors, 2) experimental studies to test hypotheses about their effects on aging and 3) translational studies to characterize potential beneficial and adverse effects of maintaining or modulating the level of juvenile protective factors in adult life. Juvenile protective factors (JPFs), intrinsic to an immature organism, help to maintain or enhance certain physiological functions across all or some stages of postnatal development (i.e., segment of the life span between birth and sexual maturity), but diminish or disappear as the organism transitions from one maturational stage to the next. The loss or diminution of JPFs after a given stage of postnatal development or at time of sexual maturity may contribute to the onset of deleterious aging changes (e.g., compromised stem cell function and reparative capacity) across adulthood. This FOA is uniquely focused on animal and clinical studies which involve comparisons between juvenile versus adult states or between stages of postnatal development to identify putative JPFs and their effects on aging. Studies which involve comparisons between young and old adults will not be supported by this FOA.
Wed, 18 Jan 2017 10:01:08 EST

Juvenile Protective Factors and Their Effects on Aging (R03)
Funding Opportunity PAR-17-127 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to invite pilot/feasibility projects for: 1) descriptive studies to identify putative juvenile protective factors, 2) experimental studies to test hypotheses about their effects on aging and 3) translational studies to characterize potential beneficial and adverse effects of maintaining or modulating the level of juvenile protective factors in adult life. Juvenile protective factors (JPFs), intrinsic to an immature organism, help to maintain or enhance certain physiological functions across all or some stages of postnatal development (i.e., segment of the life span between birth and sexual maturity), but diminish or disappear as the organism transitions from one maturational stage to the next. The loss or diminution of JPFs after a given stage of postnatal development or at time of sexual maturity may contribute to the onset of deleterious aging changes (e.g., compromised stem cell function and reparative capacity) across adulthood. This FOA is uniquely focused on animal and clinical studies which involve comparisons between juvenile versus adult states or between stages of postnatal development to identify putative JPFs and their effects on aging. Pilot studies which involve comparisons between young and old adults will not be supported by this FOA.
Wed, 18 Jan 2017 10:01:14 EST

Quantitative Imaging Tools and Methods for Cancer Therapy Response Assessment (UG3/UH3)
Funding Opportunity PAR-17-128 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages research project applications under the cooperative agreement (UG3/UH3) mechanism to address the development, optimization and validation of quantitative imaging (QI) software tools and methods for prediction and/or measurement of response to cancer therapies or for planning and validating radiation therapy treatment strategies in clinical trials.
Thu, 19 Jan 2017 11:50:56 EST

Quantitative Imaging Tools and Methods for Cancer Response Assessment (U01)
Funding Opportunity PAR-17-129 from the NIH Guide for Grants and Contracts. This purpose of this Funding Opportunity Announcement (FOA) is to provide a mechanism of support to research organizations interested in clinically translating already optimized quantitative imaging software tools capable of measuring or predicting the response of cancer to clinical therapies, or in translating imaging tools for planning and validating radiation therapy treatment strategies in clinical trials. The quantitative tools must have been developed and optimized during a performance period in the Quantitative Imaging Network (QIN) or under other separate funding. The proposed research effort should be an extension of the research that successfully completed the tasks of developing and optimizing the chosen software tools or data collection methods intended to facilitate clinical decision making during clinical trials. This FOA is intended to support the efforts of validating those tools in prospective multisite clinical trials in order to test tool performance and to demonstrate that the tool can be integrated into clinical workflow with a minimum of disruption.
Thu, 19 Jan 2017 11:50:58 EST